Webdisclosure.com

Search

UCB (EBR:UCB) UCB Media Room: New UK Campus

Directive transparence : information réglementée

16/10/2020 07:04
https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb513= 9PTmAm2ORJ-2Fb7C-2B6emLUbMCiVpd-2FSt3lIyz25ETXk2xJ79rVE0RLp3qyJ-2BVNC2TgoN5= zZtr-2BR6gBr3BCdX5jmazYnaCMlUJyTM75ysQ121E_xDPID0vOuylFAU8fv4e60wei4JxqEGBd= VWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9= c9g1waEy87aF0bD2WHd8isGOrBJooV8vI8mL3yFzLwR8eDuXQieMeTsdfgNz4XvSYhYEqFL4pH1= UZwFBxqE4lxV991nENaVfenwGXp85YtLiVEoEBWn1I8SU5SgmlGrRqui0mbZ-2FMuBSFTGuWb-2= BRfSROlKlb7iv0UBFpjb6Tyvf-2FE6zavCrZiCrInb4uOrQDqPApFgaQSdV7mQRMeV31IZT7E2M= LSM0mXGI97A30BTnSKG2h2-2BeQrZefiyPkxNhwFwPJdg-3D ** UCB FURTHER INVESTS IN UK OPERATIONS WITH AGREEMENT TO ACQUIRE A NEW LEA= DING-EDGE CAMPUS ------------------------------------------------------------ =C2=B7 UCB has signed an agreement to acquire a new campus for its UK opera= tions located in Windlesham, Surrey=C2=A0 =C2=B7 The campus will become home to one of UCB=E2=80=99s three global R&D= hubs bolstering its cutting-edge R&D, early manufacturing and commercial o= perations in the UK =C2=B7 Reinforcing its investment in the UK, this transition to a state-of-= the-art facility will deliver against UCB=E2=80=99s promise to invest more = than =C2=A31 billion over five years and support more than 650 high-value j= obs=C2=A0 Slough, UK and Brussels, Belgium =E2=80=93 16 October 2020 =E2=80=93 UCB ha= s signed an agreement to acquire a new campus for its UK operations support= ing cutting-edge research and development, early manufacturing and commerci= alisation of medicines aiming to transform the lives of people living with = severe immunological and neurological conditions. The acquisition of the world-class site in Windlesham, Surrey is anticipate= d to be completed in November 2020 and reflects UCB=E2=80=99s commitment to= retain the UK as one of its three global hubs for research and development= , alongside Belgium and the US.=C2=A0 UCB=E2=80=99s projected investment in the UK, including this site, will be = more than =C2=A31 billion over five years and the transition to this new fa= cility will support more than 650 high-value jobs in scientific research, t= ranslational medicine, clinical development, early manufacturing and commer= cial roles. The 47-acre (19 hectare) campus will be acquired from Eli Lilly and Company= Limited and was formerly its second largest research site worldwide. Follo= wing completion of the acquisition, the site will undergo state-of-the-art = refurbishment prior to UCB relocating from its current UK headquarters in S= lough, Berkshire. This refurbishment will enable successful execution of UC= B=E2=80=99s research plan to develop innovative treatments for patients inc= luding gene therapies and translational medicine, as well as development of= UCB=E2=80=99s world-class antibody discovery platforms. This new campus in Windlesham reinforces UCB=E2=80=99s conviction in UK lif= e sciences and its drive in developing innovative treatments for patients w= ith neurological and immunological conditions. UCB reinvests between 23-28%= of its revenue into R&D per annum globally, making the company one of the = most research-intensive companies in Europe. With an extensive network of c= ollaborations with UK universities, charities and other companies, UCB ende= avours to further advance scientific research in the UK and deliver the sol= utions that patients need globally. =C2=A0 Business and Industry Minister Nadhim Zahawi said: =E2=80=9CIt=E2=80=99s fa= ntastic to see that UCB has re-affirmed its commitment to the UK=E2=80=99s = world-leading life sciences sector, and I welcome the role this facility wi= ll play in creating hundreds of high value jobs in the years to come. =C2=A0=E2=80=9CUCB=E2=80=99s investment demonstrates the huge opportunity f= or companies investing in UK science and research with government support, = cementing the UK=E2=80=99s status as a global science superpower.=E2=80=9D Health Minister Lord Bethell said: =E2=80=9CThis investment is a major vote= of confidence in our incredible life sciences sector and is further proof = the UK continues to lead the way in ground-breaking medical research. =E2=80=9CThis Government will always do everything it can to ensure NHS pat= ients are the first to benefit from cutting-edge treatments.=C2=A0 =E2=80=9CDeveloping an environment that allows research and development to = thrive is the best way to allow UK innovation to flourish.=E2=80=9D Life Science's Champion Professor Sir John Bell said: =E2=80=9CWe have made= huge progress since the Industrial Strategy was published in 2017 towards = making the UK a global hub for life sciences. =E2=80=9CToday=E2=80=99s announcement from UCB is a further illustration of= the research, health and economic benefits that can be achieved through in= vestment in the UK=E2=80=99s life sciences sector.=E2=80=9D Jean-Christophe Tellier, Chief Executive Officer at UCB said: =E2=80=9CWe h= ave a strong track record of discovering medicines in the UK which go on to= make a difference to the lives of patients worldwide. I am delighted to ha= ve signed an agreement to secure this new campus for our UK hub, from which= our scientists will be able to continue to develop their extensive collabo= rations with some of the most innovative universities, bio-techs and medica= l research charities, bringing even greater benefit for patients. =E2=80=9CThis new UK site will not only support our ambitions for future dr= ug discovery but will be well-placed to enable us to achieve our 2030 globa= l sustainability goals and provides an environment which supports the physi= cal and mental wellbeing of our people =E2=80=93 essential to helping us th= rive.=E2=80=9D Worldwide UCB=E2=80=99s global footprint has been strengthened significantl= y in recent times allowing the company to meet its ambitions for patient-fo= cused medicines of the future. Alongside the new UK site, these include acq= uisition of Ra Pharma enhancing UCB=E2=80=99s innovation capabilities in th= e US and substantial investments in the Belgian Braine l=E2=80=99Alleud cam= pus. Ends Notes to Editors About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With 7 500 people in approxima= tely 40 countries, the company generated revenue of =E2=82=AC 4.9 billion i= n 2019. UCB is listed on Euronext Brussels (symbol: UCB). Contact UCB:=C2=A0 UK Communications Karen Borrer karen.borrer@ucb.co.uk +44 (0)1753 713006 +4= 4 (0) 7775 003538 Corporate Communications Laurent Schots Laurent.schots@ucb.com +32 (0)2 559= 92 64=C2=A0=C2=A0 Investor Relations Antje Witte antje.witte@ucb.com =C2=A0+32 (0)2 559 94 14= =C2=A0 Investor Relations Isabelle Ghellynck, isabelle.ghellynck@ucb.com +32 (0)2 = 559 9588=C2=A0 About the Windlesham site The site in Windlesham, Surrey is a 47-acre (19 hectare), internationally r= ecognised life sciences research and development campus. Currently owned by= Eli Lilly and Company Limited, following completion of the acquisition by = UCB, the site will undergo extensive refurbishment before relocation by UCB= from its current location in Slough, Berkshire. Forward looking statements - UCB This press release contains forward-looking statements based on current pla= ns, estimates and beliefs of management. All statements, other than stateme= nts of historical fact, are statements that could be deemed forward-looking= statements, including estimates of revenues, operating margins, capital ex= penditures, cash, other financial information, expected legal, political, r= egulatory or clinical results and other such estimates and results.=C2=A0 By their nature, such forward-looking statements are not guarantees of futu= re performance and are subject to risks, uncertainties and assumptions whic= h could cause actual results to differ materially from those that may be im= plied by such forward-looking statements contained in this press release. I= mportant factors that could result in such differences include: changes in = general economic, business and competitive conditions, the inability to obt= ain necessary regulatory approvals or to obtain them on acceptable terms, c= osts associated with research and development, changes in the prospects for= products in the pipeline or under development by UCB, effects of future ju= dicial decisions or governmental investigations, product liability claims, = challenges to patent protection for products or product candidates, changes= in laws or regulations, exchange rate fluctuations, changes or uncertainti= es in tax laws or the administration of such laws and hiring and retention = of its employees.=C2=A0 UCB is providing this information as of the date of this press release and = expressly disclaims any duty to update any information contained in this pr= ess release, either to confirm the actual results or to report a change in = its expectations. There is no guarantee that new product candidates in the pipeline will prog= ress to product approval or that new indications for existing products will= be developed and approved. Products or potential products which are the su= bject of partnerships, joint ventures or licensing collaborations may be su= bject to differences between the partners. Also, UCB or others could discov= er safety, side effects or manufacturing problems with its products after t= hey are marketed. Moreover, sales may be impacted by international and dome= stic trends toward managed care and health care cost containment and the re= imbursement policies imposed by third-party payers as well as legislation a= ffecting biopharmaceutical pricing and reimbursement. GenericFile UCB UK New Site Announcement Press Release Final (https://u7061146.ct.sendg= rid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb5139PTmAm2ORJ-2Fb7C-2B6emLUb= MCiVpd-2FSt3lIyz25ETxiP0Z-2Btt-2FavZd4LBWcF4IpksZ3hfWudB8DvApRyyjtY-3DVwj6_= xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2F= BZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1waEy87aF0bD2WHd8isGOrBJooV8vI8mL3yFzLwR= 8eDuXQieMeTsdfgNz4XvSYhYEqFL4pH1UZwFBxqE4lxV991nENaVfenwGXp85YtLiVEoEL9AWL0= REp0RXklxayKSBogFcze23-2FghsCOisYpdnjOzEHYUIHv-2FRDoc-2B8qyzdJYMeCuPEOIpRFW= -2BnUncSwvskmV4n-2BWiZVbr3eqvHI72j2xcMvlFarHvGQzR6CqRySNFOvxoJXjBTrWxkcbvq5= zN-2FM-3D=0D =0D ______________________=0D If you would rather not receive future communications from UCB SA, please g= o to https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jAT= UeYfdhr1xEBQnaPhR2RKx1tfe2VKDZTewv5u80JomRcX0D43KpbN1ZE2-2Bjm5CvUNZMMxxNJCw= tSkC44-2FXn6mkqsHSW-2Bn3tfJvxVHkLerH3pGjlXA8H7Q8NQvUNm2EH3ZbF25VhStVtxWdZAi= fJdXuT0-3DmX8w_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0Kx= vPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1waEy87aF0bD2WHd8isGOrBJo= oV8vI8mL3yFzLwR8eDuXQieMeTsdfgNz4XvSYhYEqFL4pH1UZwFBxqE4lxV991nENaVfenwGXp8= 5YtLiVEoEDrswLUTjlaKZZeTRhTwZcWOv-2B-2Bu4qrrSy-2BYxlqJiFk7z-2BxYHOs3IvevQIh= iFl6u1yOHiTKcuCL7HWpdYQkqIIfgvtbfpXZGGDivSZKan6Q2FDb6WV5wkKrSRDcw-2BTbTm8oO= tEmNzFjIsakqdKp7Vzo-3D=0D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=

16/10/2020 07:04
09/10/2020 20:04
02/10/2020 20:03
02/10/2020 07:03
25/09/2020 20:03
22/09/2020 07:03
11/09/2020 20:03
09/09/2020 07:07
09/09/2020 07:03
04/09/2020 20:03